% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kebir:821111,
      author       = {Kebir, Sied and Rauschenbach, Laurèl and Galldiks, Norbert
                      and Schlaak, Max and Hattingen, Elke and Landsberg, Jennifer
                      and Bundschuh, Ralph A. and Langen, Karl-Josef and
                      Scheffler, Björn and Herrlinger, Ulrich and Glas, Martin},
      title        = {{D}ynamic {O}-(2-[18{F}]fluoroethyl)-{L}-tyrosine {PET}
                      imaging for the detection of checkpoint inhibitor-related
                      pseudoprogression in melanoma brain metastases},
      journal      = {Neuro-Oncology},
      volume       = {18},
      number       = {10},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2016-06354},
      pages        = {1462 - 1464},
      year         = {2016},
      abstract     = {Identifying patients with pseudoprogression, which is
                      characterized by an initial increase of contrast-enhancing
                      lesions that resolve or at least stabilize spontaneously on
                      follow-up imaging without any treatment change, is critical
                      for avoiding premature termination of potentially effective
                      treatment. With the advent and success of checkpoint
                      inhibitors such as ipilimumab, nivolumab, or pembrolizumab
                      in particular, detecting pseudoprogression in patients with
                      malignant melanoma has become a major challenge in clinical
                      practice given a frequency as high as $7\%–10\%$ of
                      cases.1,2 Diagnosing progressive disease and excluding
                      pseudoprogression in melanoma metastases using the
                      immune-related Response Criteria (irRC)2 require the initial
                      increase of at least $25\%$ in lesions load to be confirmed
                      by follow-up imaging at least 4 weeks later.2 However,
                      particularly for brain metastases from malignant melanoma,
                      follow-up imaging might not be feasible for patients with
                      clinical deterioration at the time of initial increase of
                      lesions load. These patients might not be able to wait 4
                      weeks for a follow-up investigation to decide on},
      cin          = {INM-3 / INM-4 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      $I:(DE-82)080010_20140620$},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000386162800016},
      pubmed       = {pmid:27591333},
      doi          = {10.1093/neuonc/now154},
      url          = {https://juser.fz-juelich.de/record/821111},
}